Weill Cornell Medicin

407 East 61st Street
New York, New York 10065

We've found

1 trials

at this facility

Targeted Therapy With the IDH2-Inhibitor Enasidenib (AG221) for High-Risk IDH2-Mutant Myelodysplastic Syndrome

Status: Enrolling, Phase II
Updated: 12/31/1969

from

New York, NY

Use our guide to learn which trials are right for you!